Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges-Reference-Cited by-同舟云学术

Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges

Published:2024-07-22 Issue:14 Volume:16 Page:2610
ISSN:2072-6694
Container-title:Cancers
language:en
Short-container-title:Cancers

Author:

Cortinovis Diego Luigi¹²^ORCID,Leonetti Alessandro³^ORCID,Morabito Alessandro⁴^ORCID,Sala Luca²^ORCID,Tiseo Marcello³⁵^ORCID

Affiliation:

1. Division of Medical Oncology, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy

2. School of Medicine and Surgery, University of Milano Bicocca, 20126 Milan, Italy

3. Medical Oncology Unit, University Hospital of Parma, 43126 Parma, Italy

4. Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, 80131 Naples, Italy

5. Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy

Abstract

Background: Targeted therapies changed the treatment of advanced oncogene-addicted non-small cell lung cancer and could also improve outcomes in resectable disease. Results: The ALINA trial evaluated the clinical benefit of adjuvant alectinib compared with standard chemotherapy and met the primary endpoint with a significant increase in disease-free survival at 2 years among anaplastic lymphoma kinase positive patients with stage IB-IIIA disease; two phase II trials (ALNEO and NAUTIKA1) are currently evaluating perioperative treatment with alectinib, and the results of the case reports published to date are encouraging. Conclusion: In resectable anaplastic lymphoma kinase-positive lung cancer, adjuvant alectinib represents the new standard of care and could soon be used in perioperative treatment.

Publisher

MDPI AG

Link

https://www.mdpi.com/2072-6694/16/14/2610/pdf

Reference44 articles.

1. World Health Organization (2023, January 19). Cancer, Available online: https://www.who.int/news-room/fact-sheets/detail/cancer.

2. Targeted Therapies for Lung Cancer Patients with Oncogenic Driver Molecular Alterations;Tan;J. Clin. Oncol.,2022

3. Final Overall Survival Analysis from a Study Comparing First-Line Crizotinib versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer;Solomon;J. Clin. Oncol.,2018

4. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer;Peters;N. Engl. J. Med.,2017

5. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial;Camidge;J. Thorac. Oncol.,2021